Total: $230.14M
Company
(Symbol)#
(M)		 Type Of
Financing		 Number
Of
Shares,
Units
Or Warrants 		Amount
Raised
(M)		 Investors; Placement
Agents; Details
(Date)@
Adherex
Technologies
Inc. (AMEX:ADH)		 Private placement of units 30.3U $10 Versant Partners Inc. agreed to purchase 30.3M units priced at 33 cents each; it also may buy an additional 45.5M units at the same price for additional proceeds of $15M; each unit consists of one common share and one-half of a common share purchase warrant (1/22)
Advanced
Viral Research
Corp. (OTC BB:
ADVR)		 Private placement of convertible notes and warrants N/A and 48.1W $1.5 The three-year, 9% notes were purchased by Cornell Capital Partners; the notes are convertible into stock at the lesser of $0.0312 per share, or 95% of the lowest 30-day price; the five- year warrants are exercisable at $.0312 per share (1/8)
Avalon
Pharmaceuticals
Inc. (AVRX)		 Private placement of common stock 3S $10 Company agreed to sell to institutional investors 3M shares at $3.34 each; investors were Federated Kaufman Funds, Merlin Nexus II LP, Passport Management LLC, Xmark Opportunity Funds and Biotechnology Value Fund (1/23)
Bionovo Inc.
(OTC BB:BNVI)		 Private placement N/A $15.7 RA Capital participated in the round, along with Paramount BioCapital Asset Management, Ironwood Capital and a group of new and existing private shareholders (1/22)
Cortex
Pharmaceuticals
Inc. (AMEX:COR)		 Private placement of common stock and warrants 5S and W for 3.3S $5.6 Several institutional investors agreed to purchase the stock; the warrants can be exercised for $1.66 per share; Roth Capital Partners acted as exclusive placement agent (1/17)
ExonHit
Therapeutics
SA (France;
Euronext:ALEHT)		 Exercise of warrants W for 0.410S $4.1 ExonHit received $4.1M through the exercise of warrants leading to the issuance of 409,815 new shares (1/25)
FermaVir
Pharmaceuticals
Inc. (OTC BB:FMVR)		 Private placement of shares and warrants 1.693S and W for 3.387S $1.27 FermaVir raised $1.27M selling its shares and 10- year warrants (1/16)
Genelabs
Technologies
Inc. (GNLB)		 Equity sale 7.1S $2.2 Genelabs sold 7.1M shares, its remaining equity, in Genovate Biotechnology Co. Ltd., of Taiwan (1/29)
GPC Biotech
AG (Germany;
GPCB)		 Private placement of stock 1.6S |33.6 (US$43.7) GPC priced the shares at |21.50 each (1/24)
Icagen Inc.
(ICGN)		 Private placement of common stock and warrants 15.4S and W for 5.4S $22 Investors included Greenway Capital, QVT, Venrock Associates, Alta Partners and an affiliate of Quintiles Transnational Corp. (1/29)
Inflazyme
Pharmaceutical
Ltd. (Canada;
TSX:IZP)		 Private placement of units 17.6U C$3 (US$2.54) Inflazyme agreed to issue 17.6M units at 17 cents per unit (1/24)
International
Stem Cell Corp.
(OTC BB:ISCO)		 Private placement of capital stock ND $11.2 International Stem Cell raised $11.2M prior to its share exchange transaction with BTHC III Inc. (1/8)
Matritech Inc.
(AMEX:MZT)		 Private placement of secured convertible promissory notes Notes and W for 4.16S $4.36 Matritech closed a $4.36M private placement of Series B 15% secured convertible promissory notes and five-year warrants to purchase about 4.16M shares; investors were SDS Capital Group SPC Ltd., H&Q Life Science Investors and various ProMed funds (1/23)
MicroIslet Inc.
(AMEX:MII)		 Private loan W for 0.5S $2 Chairman John Hagenbuch is providing a $2M cash l oan in exchange for a 10-year warrant allow- him to purchase up to 500,000 shares at $1 each (1/16)
Monogram
Biosciences
Inc. (MGRM)		 Private placement of convertible senior unsecured notes N/A $30 The 0% convertible senior unsecured notes due 2026 were sold to a single institutional buyer (1/12)
Napo
Pharmaceuticals
Inc. (LSE:NAPL)		 Private placement of stock 3.514S £3.15 ($6.2) The shares were placed at 94.5 pence each, the Jan. 5 closing price (1/8)
Targeted
Genetics
Corp. (TGEN)		 Private placement of stock and warrants 2.18S and 0.763W $8.72 The stock was sold at $4 per share, a 16% discount to the 45-day average; the warrants are exercisable at $5.41per share; the lead investor was Special Situations Fund; Greenway Capital also invested; Pacific Growth Equities LLC was placement agent (1/8)
Resverlogix
Corp. (Canada;
TSX:RVX)		 Private placement of convertible notes and warrants N/A and 0.41W $17 The three-year, 8% notes are convertible into stock at C$12.07 per share; the warrants are exercisable C$15.09 per share; Oppenheimer & Co. Inc. was placement agent; Caris 7 Co. was co-agent (1/2)
SkyePharma
plc (UK; SKYE)		 Private placement of stock 61.2S £14.8 ($29) SkyePharma is placing up to 61.2M shares at 24.5 pence per share (1/9)
Stem Cell
Therapeutics
Corp. (Canada;
CDNX:SSS)		 Private placement of units N/A C$2 (US$1.7) Each C20-cent unit is comprised of one common share and one half of one common share purchase warrant exercisable for 24 months at C25 cents (1/22)
Wex
Pharmaceuticals
Inc. (Canada; TSX:WXI)		 Private placement of stock 8.75S C$1.575 ($1.35) Investors purchased the shares at C$0.18 each (1/9)
Notes:
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt.
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
Currency conversions are based on exchange rates at the time of the deal.
N/A = Not applicable; ND = Not disclosed.
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.